NEW YORK - A US review panel on Thursday recommended loosening restrictions on the much hyped peptide BPC-157, voting that specialized pharmacies be allowed to produce it despite alarm bells from medical experts over safety concerns.
The vote came as part of a two-day meeting by the panel tasked with considering whether seven total peptides should be added to the approved compounding list, which allows facilities to create custom drugs that will in turn be more accessible to the public.
